These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 38965571)
1. Comprehensive analysis and identification of subtypes and hub genes of high immune response in lung adenocarcinoma. Li H; Lei Y; Lai X; Huang R; Xiang Y; Zhao Z; Fang Z; Lai T BMC Pulm Med; 2024 Jul; 24(1):324. PubMed ID: 38965571 [TBL] [Abstract][Full Text] [Related]
2. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes. Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020 [TBL] [Abstract][Full Text] [Related]
3. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma. Yang P; He S; Ye L; Weng H Int Arch Allergy Immunol; 2024; 185(9):910-920. PubMed ID: 38781935 [TBL] [Abstract][Full Text] [Related]
4. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma. Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L Front Immunol; 2021; 12():723172. PubMed ID: 34539658 [TBL] [Abstract][Full Text] [Related]
5. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay. Liang H; Li Y; Qu Y; Zhang L Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574 [TBL] [Abstract][Full Text] [Related]
6. FOXA1/UBE2T Inhibits CD8 Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180 [TBL] [Abstract][Full Text] [Related]
7. CD8 Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H Front Immunol; 2022; 13():806877. PubMed ID: 35273597 [TBL] [Abstract][Full Text] [Related]
8. HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma. Chen Z; Wang Y; Tang W; Xu S; Yu H; Chen Z J Immunother; 2024 Oct; 47(8):313-322. PubMed ID: 39005046 [TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ Front Genet; 2022; 13():1017866. PubMed ID: 36699466 [No Abstract] [Full Text] [Related]
10. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q Front Immunol; 2021; 12():693062. PubMed ID: 34497605 [TBL] [Abstract][Full Text] [Related]
11. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy. Liao Y; He D; Wen F Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518 [TBL] [Abstract][Full Text] [Related]
12. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619 [TBL] [Abstract][Full Text] [Related]
13. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma. Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma. Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698 [TBL] [Abstract][Full Text] [Related]
15. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. Lu Y; Wu F; Cao Q; Sun Y; Huang M; Xiao J; Zhou B; Zhang L Oncogene; 2022 Jan; 41(5):704-717. PubMed ID: 34839353 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of PPP4C's impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics. Wang K; Peng B; Xu R; Lu T; Chang X; Shen Z; Shi J; Li M; Wang C; Zhou X; Xu C; Chang H; Zhang L Front Immunol; 2024; 15():1416632. PubMed ID: 39026674 [TBL] [Abstract][Full Text] [Related]
17. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma. Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482 [TBL] [Abstract][Full Text] [Related]
18. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J Front Immunol; 2023; 14():1217590. PubMed ID: 37492563 [TBL] [Abstract][Full Text] [Related]
19. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408 [TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]